Plasma Exchange Cuts Blood Microplastics by 60%: First Clinical Data
BiohackingAmericans ingest an estimated 39,000 to 52,000 microplastic particles annually. Until May 2026, there was no peer-reviewed data on whether any clinical intervention could meaningfully remove them from circulation.
The Number
A study published in the Journal of Clinical Apheresis analyzed blood samples from more than 100 patients at Circulate Health clinics. Among patients with elevated baseline levels (at least 30 microplastic particles per 100µL of blood), therapeutic plasma exchange reduced mean microplastic concentrations from 52.2 to 21.1 MP/100µL — a reduction of roughly 60%, with statistical significance at p < 0.001.
The measurement used Circulate Health’s PlasticTox assay on 100µL blood samples, with the Spectra Optia Apheresis System from Terumo BCT handling the exchange procedure. The protocol removes blood plasma and replaces it with a sterile 5% albumin solution, eliminating particles that circulate in the plasma fraction.
How the Math Works
Plasma exchange has been used clinically for decades to treat conditions like myasthenia gravis and Guillain-Barré syndrome — the microplastic reduction finding is an incidental benefit of existing, established clinical infrastructure, not a novel procedure developed for this purpose. The mechanism is straightforward: microplastics circulate dissolved in plasma, so replacing the plasma removes them. What wasn’t known before this study is how significant that removal is in practice.
The 60% figure applies to the subset of patients with elevated baseline burden (>30 MP/100µL). The study doesn’t report outcomes for lower-baseline patients, and critically, it doesn’t address how quickly microplastic levels rebound after treatment. Rebound rate is essential for understanding whether this is a durable intervention or a temporary reduction that normalizes within weeks.
The study was announced by Circulate Health, which operates the clinics where patients were treated — a stakeholder with obvious commercial interest in positive results. The Journal of Clinical Apheresis is peer-reviewed, the statistical threshold is conventional, and the findings warrant replication by independent researchers.
What It Signals
This is the first study to quantify microplastic clearance in humans using a standardized assay. That’s the significance — not the 60% figure in isolation, but the establishment of a measurement methodology (PlasticTox) and a proof-of-concept mechanism. Future research can now ask: how quickly do levels rebound? Do specific microplastic size fractions clear differently? Does particle reduction produce measurable downstream health changes?
For the longevity and biohacking community, plasma exchange is already documented as a protocol for removing senescent cell signals and aged plasma factors. The microplastic finding adds another potential rationale — one that intersects with environmental health exposure rather than biological aging per se.
The So What
The study establishes that clinical removal of blood microplastics is measurable and significant in magnitude. What it doesn’t establish — yet — is whether that removal translates to any health outcome. That’s the study that still needs to happen. For practitioners already performing plasma exchange for other indications, the microplastics data warrants tracking pre- and post-treatment levels as a longitudinal data point. For the broader community, the finding is worth monitoring but not worth acting on until replication and rebound data exist.
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →